

Consolidated Balance Sheets

	As of March 31,		As of
	2020	2019	December 31,
	Unaudited		Audited
	U.S Dollars in thousands		
<u>Assets</u>			
<u>Current Assets</u>			
Cash and cash equivalents	\$ 49,288	\$ 22,037	\$ 42,662
Short-term investments	47,124	33,800	31,245
Trade receivables, net	26,266	23,210	23,210
Other accounts receivables	1,736	3,442	3,272
Inventories	41,787	31,708	43,173
Total Current Assets	<u>166,201</u>	<u>114,197</u>	<u>143,562</u>
<u>Non-Current Assets</u>			
Property, plant and equipment, net	24,379	24,642	24,550
Right-of-use assets	3,800	4,187	4,022
Other long term assets	1,053	174	352
Deferred expenses	421	-	-
Deferred taxes	939	1,895	1,311
Total Non-Current Assets	<u>30,592</u>	<u>30,898</u>	<u>30,235</u>
Total Assets	<u>\$ 196,793</u>	<u>\$ 145,095</u>	<u>\$ 173,797</u>
<u>Liabilities</u>			
<u>Current Liabilities</u>			
Current maturities of bank loans	\$ 465	\$ 470	\$ 489
Current maturities of lease liabilities	928	961	1,020
Trade payables	18,440	15,255	24,830
Other accounts payables	4,875	4,424	5,811
Deferred revenues	649	461	589
Total Current Liabilities	<u>25,357</u>	<u>21,571</u>	<u>32,739</u>
<u>Non-Current Liabilities</u>			
Bank loans	138	591	257
Lease liabilities	3,663	4,036	3,981
Deferred revenues	569	605	232
Employee benefit liabilities, net	1,251	823	1,269
Total Non-Current Liabilities	<u>5,621</u>	<u>6,055</u>	<u>5,739</u>
<u>Shareholder's Equity</u>			
Ordinary shares	11,647	10,412	10,425
Additional paid in capital net	204,702	179,352	180,819
Capital reserve due to translation to presentation currency	(3,490)	(3,490)	(3,490)
Capital reserve from hedges	264	11	8
Capital reserve from financial assets measured at fair value through other comprehensive income	-	118	145
Capital reserve from share-based payments	8,903	9,463	8,844
Capital reserve from employee benefits	(356)	4	(359)
Accumulated deficit	(55,855)	(78,401)	(61,073)
Total Shareholder's Equity	<u>165,815</u>	<u>117,469</u>	<u>135,319</u>
Total Liabilities And Shareholder's Equity	<u>\$ 196,793</u>	<u>\$ 145,095</u>	<u>\$ 173,797</u>

Consolidated Statements of Comprehensive Income

	Three months period ended		Year ended
	March 31,		December 31,
	2020	2019	2019
	Unaudited		Audited
	U.S Dollars in thousands		
Revenues from proprietary products	\$ 25,317	\$ 20,381	\$ 97,696
Revenues from distribution	7,973	6,416	29,491
Total revenues	33,290	26,797	127,187
Cost of revenues from proprietary products	14,947	10,490	52,425
Cost of revenues from distribution	6,892	5,123	25,025
Total cost of revenues	21,839	15,613	77,450
Gross profit	11,451	11,184	49,737
Research and development expenses	3,347	2,766	13,059
Selling and marketing expenses	940	1,092	4,370
General and administrative expenses	2,312	2,094	9,194
Other expense	2	23	330
Operating income	4,850	5,209	22,784
Financial income	317	280	1,146
Income (expense) in respect of securities measured at fair value, net	102	(52)	(5)
Income (expense) in respect of currency exchange differences and derivatives instruments, net	432	(313)	(651)
Financial expense	(77)	(71)	(293)
Income before tax on income	5,624	5,053	22,981
Taxes on income	406	130	730
Net Income	\$ 5,218	\$ 4,923	\$ 22,251
Other Comprehensive Income (loss) :			
Amounts that will be or that have been reclassified to profit or loss when specific conditions are met			
Gain (loss) from securities measured at fair value through other comprehensive income	(188)	108	143
Gain on cash flow hedges	241	74	92
Net amounts transferred to the statement of profit or loss for cash flow hedges	34	(2)	(23)
Items that will not be reclassified to profit or loss in subsequent periods:			
Remeasurement gain (loss) from defined benefit plan	-	-	(388)
Tax effect	27	(28)	(11)
Total comprehensive income	\$ 5,332	\$ 5,075	\$ 22,064
<u>Earnings per share attributable to equity holders of the Company:</u>			
Basic income per share	\$ 0.12	\$ 0.12	\$ 0.55
Diluted income per share	\$ 0.12	\$ 0.12	\$ 0.55

Consolidated Statements of Cash Flows

	Three months period Ended		Year Ended
	March 31,		December 31,
	2020	2019	2019
	Unaudited		Audited
	U.S Dollars in thousands		
Net income	\$ 5,218	\$ 4,923	\$ 22,251
Adjustments to reconcile net income to net cash provided by operating activities:			
Adjustments to the profit or loss items:			
Depreciation and impairment	1,192	1,127	4,519
Financial expenses (income), net	(774)	156	(197)
Cost of share-based payment	258	315	1,163
Taxes on income	406	130	730
Loss (gain) from sale of property and equipment	-	(6)	(2)
Change in employee benefit liabilities, net	(18)	36	94
	<u>1,064</u>	<u>1,758</u>	<u>6,307</u>
Changes in asset and liability items:			
Decrease (increase) in trade receivables, net	(3,016)	4,727	5,117
Decrease (increase) in other accounts receivables	1,513	131	(214)
Decrease (increase) in inventories	1,386	(2,392)	(13,857)
Decrease (increase) in deferred expenses	(421)	(246)	399
Increase (decrease) in trade payables	(7,216)	(2,368)	6,259
Increase (decrease) in other accounts payables	(1,180)	(510)	863
Increase (decrease) in deferred revenues	397	(63)	(283)
	<u>(8,537)</u>	<u>(721)</u>	<u>(1,716)</u>
Cash received (paid) during the year for:			
Interest paid	(55)	(63)	(243)
Interest received	451	172	1,106
Taxes paid	(61)	(8)	(134)
	<u>335</u>	<u>101</u>	<u>729</u>
<u>Net cash provided by (used in) operating activities</u>	<u>\$ (1,920)</u>	<u>\$ 6,061</u>	<u>\$ 27,571</u>

Consolidated Statements of Cash Flows

	Three months period Ended		Year Ended
	March 31,		December 31,
	2020	2019	2019
	Unaudited		Audited
	U.S Dollars in thousands		
<u>Cash Flows from Investing Activities</u>			
Investment in short term investments, net	\$ (15,646)	\$ (1,058)	\$ 1,727
Purchase of property and equipment and intangible assets	(896)	(304)	(2,300)
Proceeds from sale of property and equipment	-	6	9
Net cash used in investing activities	<u>(16,542)</u>	<u>(1,356)</u>	<u>(564)</u>
<u>Cash Flows from Financing Activities</u>			
Proceeds from exercise of share base payments	5	3	16
Repayment of lease liabilities	(278)	(263)	(1,070)
Repayment of long-term loans	(123)	(115)	(476)
Proceeds from issuance of ordinary shares, net	24,894	-	-
Net cash provided by (used in) financing activities	<u>24,498</u>	<u>(375)</u>	<u>(1,530)</u>
Exchange differences on balances of cash and cash equivalent	<u>590</u>	<u>(386)</u>	<u>(908)</u>
Increase in cash and cash equivalents	6,626	3,944	24,569
<u>Cash and cash equivalents at the beginning of the year</u>	<u>42,662</u>	<u>18,093</u>	<u>18,093</u>
<u>Cash and cash equivalents at the end of the year</u>	<u>\$ 49,288</u>	<u>\$ 22,037</u>	<u>\$ 42,662</u>
<u>Significant non-cash transactions</u>			
Purchase of property and equipment through capital lease	\$ 58	\$ 4,431	\$ 5,035
Purchase of property and equipment	\$ 579	\$ 235	\$ 992

Adjusted EBITDA

	Three months period Ended		Year ended
	March 31,		December 31,
	2020	2019	2019
	U.S. Dollars in thousands		
Net income (loss)	\$ 5,218	\$ 4,923	\$ 22,251
Taxes on income	406	130	730
Financial income, net	(774)	156	(197)
Depreciation and amortization expense	1,192	1,127	4,519
Cost of share - based payments	258	315	1,163
Adjusted EBITDA	<u>\$ 6,300</u>	<u>\$ 6,651</u>	<u>\$ 28,466</u>

Adjusted Net Income

	Three months period Ended		Year ended
	March 31,		December 31,
	2020	2019	2019
	U.S. Dollars in thousands		
Net income (loss)	\$ 5,218	\$ 4,923	\$ 22,251
Cost of share - based payments	258	315	1,163
Adjusted net income	<u>\$ 5,476</u>	<u>\$ 5,238</u>	<u>\$ 23,414</u>